Črevesni mikrobiom pri bolnikih z rakom
Gut microbiome in cancer patients
DOI:
https://doi.org/10.25670/oi2024-009onKeywords:
Gut microbiome, cancerogenesis, immunotherapy, immune checkpoint inhibitorsAbstract
Črevesni mikrobiom predstavlja genetsko zasnovo vseh mikrobov, ki obstajajo v človeškem prebavnem traktu in vsebuje približno 38 bilijonov mikroorganizmov, ki kodira več kot tri milijone genov. Razvoj novih tehnik molekularnega sekvenciranja je omogočil poglobljeno raziskovanje človeškega mikrobioma, ki je vpleten v presnovo hranil, zdravil, vzdržuje celovito bariero črevesne sluznice, varuje pred patogenimi mikroorganizmi in lahko spreminja imunski odziv gostitelja. Vse več je dokazov, da je črevesni mikrobiom vpleten v razvoj nekaterih malignih bolezni in vpliva na učinkovitost onkološkega zdravljenja, predvsem na imunoterapijo. Sedanje razumevanje številnih zapletenih interakcij med črevesnim mikrobiomom, gostiteljevim imunskim sistemom, prehrano, zdravili in malignimi celicami temelji na manjših retrospektivnih in opazovalnih raziskavah. Namen tega prispevka je pregled razpoložljivih podatkov o mikrobiomu in naše dosedanje razumevanje vloge črevesnega mikrobioma pri bolnikih z rakom.
Abstract (Eng)
The gut microbiome represents the genetic makeup of all the microbes in the human digestive tract. It contains about 38 trillion microorganisms with more than three million genes. The development of new sequencing techniques has made possible in-depth research of the human microbiome, which is involved in the metabolism of nutrients, and drugs, maintains a barrier of the intestinal mucosa, protects against pathogenic microorganisms, and can alter the host's immune response. There is compounding evidence that the microbiome is involved in the development of certain malignant diseases and affects the effectiveness of oncological treatment, specifically immunotherapy. Currently, the understanding of the numerous complex interactions between the gut microbiome, the host immune system, diet, drugs, and malignant cells is based on smaller retrospective and observational studies. This paper aims to review the available data on the microbiome and our current understanding of the role of the human microbiome in cancer patients.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jakob Ivkovič, Mojca Unk

This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.
This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.